Finance3 sources
Johnson & Johnson reports promising results for prostate cancer treatments
- Johnson & Johnson reported a 75% tumor response rate for advanced prostate cancer with JNJ-6143.
- ERLEADA® (apalutamide) treatment reduced the risk of recurrence or death by 62% in high-risk prostate cancer.
- JNJ-6143 is a first-in-class RIPTAC™ molecule.
- ERLEADA® is used before and after surgery for high-risk prostate cancer.
- Johnson & Johnson's prostate cancer drug showed tumor shrinkage in early-stage trials.
Articles (5)
Financial Times·
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule – Company Announcement - FT.com
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer – Company Announcement - FT.com
Yahoo Finance·
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Reuters·
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial